CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 49 enrolled
Drug / intervention
Ruxolitinibdrug
Likely dose
Ruxolitinib 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03616184
NCT03616184Phase 2Completed
CompareCT.gov

A Single Arm, Open Label, Phase II Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids

University of Nebraska·interventional·Posted Aug 6, 2018·Updated Oct 5, 2023

In Brief

A Phase 2 clinical trial evaluating Ruxolitinib for Graft-versus-host-disease (GVHD). Completed, enrolled 49 participants across 5 sites.

Detailed Summary

The primary objective of the study is to examine the efficacy of ruxolitinib in patients with sclerotic chronic graft-versus-host disease (GVHD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGraft-versus-host-disease (GVHD)
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedAug 6, 2018
Enrollment StartSep 5, 2018
Primary CompletionJan 22, 2022
Study CompletionJun 12, 2023
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 7.9 years ago

Interventions

Ruxolitinibdrug

Patients with sclerotic chronic graft-versus-host disease (GVHD) will receive oral ruxolitinib at a dose of 10 mg twice daily. Doses may not exceed 10 mg twice daily. Ruxolitinib will be continued for 6 months. Patients who continue to have stable disease, mixed responses or partial/complete responses at the end of 6 months may continue the drug for a total of 12 months.